Advertisement

Topics

Companies Related to "Bavarian Nordic Announces Initiation Phase Booster Study Universal" [Most Relevant Company Matches] RSS

11:21 EDT 18th September 2018 | BioPortfolio

Here are the most relevant search results for "Bavarian Nordic Announces Initiation Phase Booster Study Universal" found in our extensive corporate database of over 50,000 company records.

Showing "Bavarian Nordic Announces Initiation Phase Booster Study Universal" Companies 1–25 of 1,600+

Extremely Relevant

Bavarian Nordic

Bavarian Nordic initiated the development of IMVAMUNE® in 1999 and began the first clinical study in 2001. In 2003, Bavarian Nordic was awarded a contract, valued at $29 million, from the U.S. National Institutes of Health (NIH), for the further development of IMVAMUNE®. In 2004, Bavarian Nordic was awarded its second U.S. Government contract, valued at $115 million, to continue advanced devel...


Bavarian Nordic Research Institute A/S

Bavarian Nordic is a commercially viable international biopharmaceutical company through:Biopharmaceutical innovations Novel prophylactic and therapeutic approaches Development, production, testing and marketing of novel pharmaceutical products. Focusing on safe and efficient biopharmaceutical approaches Development of a platform technology for use against multiple infectious and cancer diseases S...

Relevant

Bavarian Nordic A/S

In 2004 we marked our 10 year anniversary as a company. Over the past decade we have developed the early MVA vector research into a broad commercial vaccine vector technology.


BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...

Medikalla Oy MedFiles

MedFiles is a private contract research organisation (CRO). We offer clinical development services from Phase I to Phase IV studies and all the way to the maintenance of marketing authorisation. Our services cover everything from study initiation to final reporting.Unrivalled experience over 19 years combined with a high degree of competency and continuous development guarantee a high standard of ...

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...

Vivus

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. Analysts speculate that the potential market for obesity ranges from $5 billion to $10 billion annually, and the indications targeted by VIVUS' sexual health products each represent a projected market greater than $1 billion annual...

Clinical Network Services (CNS)

Clinical Network Services (CNS) Pty Ltd is an Australian CRO, focused on providing full contract research organisational clinical trial services to the international healthcare community particularly during the early phase (Phase I and Phase II) clinical development of their products. CNS has established itself as Brisbane’s only headquartered Australian CRO working both nationally with dedicat...

Rapid Medical Research, Inc.

Rapid Medical Research, Inc., (RMR) is a free-standing, dedicated, multi-therapeutic clinical research center. Our professional research team includes an executive director, two physicians including a full-time onsite internist and 1 part-time OB/GYN, a regulatory specialist, four nurse coordinators, two patient recruiters, two research assistants, and an office manager. We offer a wide range of s...

BioLineRx Ltd. and Compugen Ltd.

BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx’s current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia has commenced a Phase II/III study; BL-1040 for...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

Universal Protection Service

Founded in 1965, Universal Protection Service (UPS) combines an innovative mix of tradition with cutting edge systems and technology to keep pace with the ever-evolving needs of today's business environments. Headquartered in Santa Ana, Calif., with offices located throughout Arizona, California, Colorado and Washington, UPS employs hands-on, highly experienced management teams and continuous trai...

ProFibrix B.V.

Fibrocaps is based on a mixture of two essential blood clotting proteins, fibrinogen and thrombin, and is a unique dry powder topical tissue sealant in development to stop bleeding after or during surgery. Fibrocaps is clearly differentiated from existing liquid tissue sealants and hemostats: it is ready for immediate use, is stable at room temperature, and has shown to be safe and efficacious...

Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.

Alliance for Biosecurity

The Alliance for Biosecurity was formed in June of 2005 by biopharmaceutical companies and the Center for Biosecurity of the University of Pittsburgh Medical Center. Alliance members are committed to partnering with government and promoting a new era in the prevention and treatment of severe infectious diseases - particularly those that present global security challenges - through innovative and ...

Richmond Pharmacology Ltd

Our goal is to deliver full service Early Phase clinical solutions swiftly, efficiently, and to the highest clinical standard. Our integrated set-up is designed to manage your Early Phase study within the controlled environment of Phase I. We compliment this through our out-patient facilities offering flexibility through the Phases in clinical trials.“Richmond Pharmacology is the UK's only Early...

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

Universal American Corp.

Universal American, through our family of healthcare companies, offers benefit plans designed to promote collaboration among our members and their healthcare professionals. This Healthy CollaborationSM improves, each day, the health and well-being of more than two million older and disabled Americans. For more information on Universal American, please visi...

Nordic Nanovector

Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat Non-Hodgkin Lymphoma (NHL) and other hematological malignancies.

Universal Pasteurization Company LLC

Headquartered in Villa Rica, Ga., Universal Pasteurization Company, LLC (www.universalpasteurization.com), as well as its affiliated business Universal Cold Storage, LLC is dedicated to ensuring the safety and quality of foods and beverages. As a customer-centric service provider of high pressure processing (HPP), Universal Pasteurization’s four U.S. locatio...

Universal Display Corporation

Universal Display Corporation (Nasdaq: OLED) is a leader in developing and delivering state-of-the-art, organic light emitting diode (OLED) technologies, materials and services to the display and lighting industries. To learn more about Universal Display Corporation, please visit http://www.oled.com.

Universal Health Care Group, Inc.

Universal Health Care Group is the parent company of Universal Health Care, Inc., a managed care company that has been providing Medicare Advantage Health Plans to Medicare eligible beneficiaries since 2003 – most notably the “Medicare Masterpiece® (HMO)” and “Medicare Masterpiece® (PPO)” plans, as well as Florida Medicaid be...

NPS Pharmaceuticals, Inc.

NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registration programs. Teduglutide, a proprietary analog of GLP-2, is being evaluated as GATTEX® in a Phase 3 registration study known as STEPS for intestinal failure associated with shor...

Genosco

Located in Cambridge, MA, Genosco is a clinical-stage biotechnology company led by CEO, Dr. Jong Sung (John) Koh, focusing on developing and commercializing novel immunology and oncology treatments to improve the lives of patients. Genosco’s core competence comes from its expertise in generating selective kinase inhibitors that include candidates that ...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...


More From BioPortfolio on "Bavarian Nordic Announces Initiation Phase Booster Study Universal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks